Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment
NCT ID: NCT04558164
Last Updated: 2025-03-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
70 participants
INTERVENTIONAL
2021-01-26
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Transcranial Alternating Current Stimulation for the Improvement of Episodic Memory in Healthy Older Adults
NCT06284720
Improvement of Memory in Mild Cognitive Impairment
NCT05708001
Effects of Gamma-tACS on Memory and Sleep
NCT05907707
Memory Enhancement Using Transcranial Alternating Current Stimulation
NCT06202872
Patient Centered-Rehabilitation ver111090.1
NCT03034954
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active TBS
Theta burst stimulation (TBS) will be delivered at 100% of motor threshold (MT).
Active Theta Burst Stimulation
Theta burst transcranial magnetic stimulation (TBS) will be delivered at 80-100% of motor threshold (MT).
Sham TBS
Sham stimulation will be delivered at 0% of motor threshold (MT), with all other parameters matching the active TBS condition.
Sham Theta Burst Stimulation
Sham stimulation will be delivered at 0-10% of motor threshold (MT), with all other parameters matching the active TBS condition.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Active Theta Burst Stimulation
Theta burst transcranial magnetic stimulation (TBS) will be delivered at 80-100% of motor threshold (MT).
Sham Theta Burst Stimulation
Sham stimulation will be delivered at 0-10% of motor threshold (MT), with all other parameters matching the active TBS condition.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 55-100 years of age
* Right-handedness
* In good general health
* Living independently
* Subjective memory complaints (self-report and positive score on MFQ)
* Katz ADL scale and Lawton iADL scale: We will review scores on a case-by-case basis if they did not score 100%. We will exclude if the scores show impairment in ADLs that suggests problems with independent functioning due to cognitive impairment.
* MMSE score \> 24
* PHQ Depression score =\< 7
* Ability to read, write, and speak English fluently
* Diagnosis of mild neurocognitive disorder according to DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) criteria. Participants with subjective memory complaints without an aMCI diagnosis will be reviewed on a case-by-case basis based on neuropsychological scores. Participants scoring a raw score of 0 or 3 standard deviations below normative expectations on the long delay recall in two or more of the three tasks (BVMT-R, RCFT, and CVLT-III) will be excluded.
* No change in use of psychotropic medication for treatment of depression, anxiety, ADHS or psychosis 1 month prior and during the study.
Screening diagnostic criteria for aMCI will be subjective memory complaints, intact instrumental and basic activities of daily living (Smith et al., 1996), PHQ, MMSE, BVMT-R (25-minute delay), CVLT-II (20-minute delay), Rey-Osterrieth Complex Figure Task (30-minute delay). Baseline assessments will include neuropsychological testing of all study subjects.
Exclusion Criteria
* Diagnosis of dementia
* Active major medical, psychiatric, or neurologic disorder associated with neurocognitive impairment
* History of alcohol or substance abuse
* Recent (\< 6 months) alcohol or substance abuse (excluding nicotine or caffeine)
* History of stroke (if the stroke in our judgment is related to the memory problem), traumatic brain injury with loss of consciousness, or other neurologic disorder (e.g., epilepsy, Huntington's disease, Parkinson's disease)
* Non-English speaking participants
* Not right handed based on self-report or evaluation based on a standard report
* Has received TMS before (not TMS naïve)
* Poorly controlled hypertension or cardiovascular disease
* Current enrollment in a memory-enhancement study or course
* Contraindication to TMS or MRI including claustrophobia, metal in body, surgery within 60 days, certain implants, or previous abnormal MRI results.
* scanning facial tattoos is okay if safe with MRI
* is taking:
* anticholinergic medication (e.g., Detrol, Cogentin);
* sedating antihistamine (e.g., Benadryl);
* any drug that has significant anticholinergic or antihistaminic side effects (e.g., tricyclic antidepressant medications, Remeron).
* benzodiazepines. While not a strict rule out, this will be decided on a case-by-case basis depending on the dose.
55 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Aging (NIA)
NIH
University of California, Los Angeles
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nanthia Suthana
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nanthia Suthana
Role: PRINCIPAL_INVESTIGATOR
University of California, Los Angeles
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California Los Angeles
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20-001417
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.